IMPACT OF EGFR MUTATION ON PROGNOSIS OF STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER NSCLC: A RETROSPECTIVE ANALYSIS

: Background: Patients with activating somatic mutations in the Epidermal Growth Factor Receptor (EGFR) have better prognosis when treated with Tyrosine Kinase Inhibitors (TKI) as the standard treatment of care in advanced stage NSCLC. Aim of the work: To study the impact of EGFR mutation on prognosis of advanced stage non-squamous NSCLC. Patients and Methods: This is a cross-sectional, retrospective-cohort study of stage IV non squamous non-small cell lung cancer (January 2019-june2021). This study was done at both Clinical Oncology and Nuclear Medicine department Ain Shams university Hospital and Nasser Institute Cancer Centre for research and treatment (NICC) EGFR mutation status, treatment, progression free survival, overall survival and response rate were evaluated. Primary end point: progression free survival of stage IV NSCLC with wild type and mutant EGFR. Secondary end point: overall survival of stage IV NSCLC with EGFR mutation and wild type, response rate to treatment. Results: From the 87 patients which performed screening for EGFR mutations, 20 (23%) had mutations, while 64 (73%) had wild type EGFR. The

[1]  J. Fang,et al.  OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI , 2019, Journal of Thoracic Oncology.

[2]  T. Mitsudomi,et al.  Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Cho,et al.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[5]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[6]  Júlio Oliveira,et al.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study , 2012, Tumor Biology.

[7]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[8]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[10]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[11]  J. Machado,et al.  Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer , 2013 .